Key facts
- iGENETECH’s last known valuation is $29.0M.
- It has raised $4.5M.
- Notable investors include BioPark Dx, C&Venture Partners, Innocube, SolGent.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for iGENETECH
- ·The full record, as it builds
Funding rounds
No funding rounds for iGENETECH are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iGENETECH
Developer of a technology-centered medical device venture company specializing in on-site diagnostic platforms, cartridges, and reagents for molecular diagnostics and immunoassays. The company's platform is focused on developing high-precision, compact, all-in-one automated equipment and diagnostic reagents that can be immediately deployed on-site in response to the changing trends in testing from automated equipment-based hospitals and medical examination centers to on-site testing needs by accumulating and integrating key technologies and in various fields such as biotechnology, materials, machinery, and computers, to develop practical platforms and leveraging the expertise of its core personnel to rapidly commercialize and enhance the on-site applicability of molecular and immune diagnostics, thereby providing customers with optimal solutions for rapid disease diagnosis and treatment through products that offer user-friendliness and high confidence in the results.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2022
- Employees
- 20
- Website
- igenetech.co.kr/eng
- Ownership
- Privately Held (backing)
iGENETECH doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iGENETECH shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iGENETECH in its N-PORT filings yet. We sweep new filings monthly.